|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We found mutations encoding L640I and A643T in the B3 domain of human CEACAM5 in colorectal adenocarcinomas; structural studies indicated that these mutations would alter the interaction between CEACAM5 and TGFBR1.
|
31585122 |
2020 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
CEA, CYFRA21-1 and NSE are tumor markers used for monitoring the response to chemotherapy in advanced adenocarcinoma, squamous cell carcinoma and small-cell lung cancer, respectively.
|
30849967 |
2019 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The results indicated that history of chronic obstructive pulmonary disease (OR = 2.59, 95% CI: 1.09, 6.15; P = 0.03), adenocarcinoma (OR = 2.28, 95% CI: 1.88, 2.77; P < 0.01), advanced tumour stage (TNM III-IV vs. I-II, OR = 2.38, 95% CI: 1.99, 2.86; P < 0.01), history of central venous catheter (OR = 1.95, 95% CI: 1.36, 2.78; P < 0.01), history of chemotherapy (OR = 2.32, 95% CI: 1.80, 2.99, P < 0.01), high levels of D-dimer (WMD = 4.31, 95% CI: 2.53, 6.10; P < 0.01) and carcinoembryonic antigen (WMD = 10.30, 95% CI: 9.95, 10.64; P < 0.01) and a low level of partial pressure of oxygen (WMD = -25.97, 95% CI: -31.31, -20.62; P < 0.01) were clinical features of LC patients with PE compared to those without PE.
|
31568496 |
2019 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We therefore performed a feasibility study in 9 patients with advanced gastrointestinal adenocarcinomas to explore AMG 211 biodistribution (also known as MEDI-565), an approximately 55 kDa bispecific T-cell engager (BiTE®) directed against carcinoembryonic antigen (CEA) on tumor cells and cluster of differentiation 3 (CD3) on T-cells.
|
30745297 |
2019 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumours with both squamous and adenocarcinoma features (CK5/6 and CEA positive) were most prevalent (47.5%, n=29).
|
29848682 |
2018 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Carcinoembryonic antigen (CEA) is an epithelial biomarker with a strong staining pattern in adenocarcinomas.
|
30233867 |
2018 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CEA and NSE levels were higher in adenocarcinoma and neuroendocrine tumour, respectively, while SCC-Ag and CYFRA21-1 levels were higher in squamous cell cancer.
|
30115364 |
2018 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Biopsies from the anal canal tumor, swollen lymph node, and Paget lesion all showed poorly differentiated adenocarcinoma with neuroendocrine features expressing synaptophysin and chromogranin A. Serum CEA and NSE levels were high, 809.4 ng/ml and 85.8 ng/ml, respectively.
|
30458812 |
2018 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The CEA and CA125 expression levels were associated with CT-diagnosed adenocarcinoma tumor size.
|
30250539 |
2018 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Patients with adjacent LSN metastasis (P < 0.001), solid nodule (P = 0.001), non-lepidic predominant invasive adenocarcinoma (P < 0.001), nodules with maximum diameter larger than 2 cm (P < 0.001) and those with elevated serum carcinoembryonic antigen level (>5 ng/ml) (P = 0.005) had a higher isolated LSN metastasis rate.
|
28950357 |
2018 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Multivariate logistic regression analyses revealed that compared with central SQCC, female sex, younger age, no history of smoking, higher levels of CEA and contralateral hilum lymphadenopathy were the significantly independent indicators of central pulmonary ADC.
|
29765230 |
2018 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We here present the case of an 82-year-old man with incidental early stage adenocarcinoma of the right upper lobe showing CEA elevation in pleural fluid and serum despite negative cytological findings.
|
29997989 |
2018 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We determined whether serum carcinoembryonic antigen (CEA) levels, which are usually elevated in lung adenocarcinomas, could be used to differentiate between pure SCLC and SCLC combined with adenocarcinoma.
|
29211356 |
2017 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The aim of this study is to evaluate the prognostic significance of preoperative and postoperative serum levels of carcinoembryonic antigen (CEA) and CYFRA 21-1 in patients with pathological stage I pulmonary adenocarcinoma.
|
29069854 |
2017 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This study was performed to verify the specificity and independence of serum CEA level from the other serum tumor markers especially related to adenocarcinoma.
|
28295553 |
2017 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, all specimens were invasive adenocarcinoma, with lepidic (18.6%), papillary (15.4%), acinar (52.7%), solid (9.7%), micropapillary (3.2%), and mucinous predominant (0.4%) subtypes; CEA levels in patients with the solid subtype were higher than those of other histologic subtypes (<i>P</i>=0.001).
|
28744138 |
2017 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
CYFRA21-1 and SCC-Ag were significantly higher in SCC, NSE was significantly higher in SCLC (P<0.001), and CEA was higher in adenocarcinoma (P = 0.343).
|
28877268 |
2017 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overall and recurrence-free survivals were favourable in patients with tumour size ≤3 cm, consolidation-to-tumour ratio ≤0.50, solid tumour size ≤1.2 cm, carcinoembryonic antigen level <5.0 ng/mL and adenocarcinoma.
|
28748318 |
2017 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Cyfra21-1 and CEA exhibit different predictive and prognostic values between EGFR-mutated and wild-type adenocarcinomas, as well as between EGFR mutation subtypes.
|
27072585 |
2016 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The aberrant overexpression of CEA on adenocarcinoma cells correlates with their increased metastatic potential.
|
24388361 |
2014 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Elevated serum CEA levels predict the presence of EGFR gene mutations in Chinese nonsmokers with pulmonary adenocarcinoma.
|
24487967 |
2014 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of this study was to predict EGFR mutation status in patients with pulmonary adenocarcinoma based on (18)F-fluorodeoxyglucose (FDG) uptake and imaging features in positron emission tomography/computed tomography (PET/CT), as well as on the serum carcinoembryonic antigen (CEA) level.
|
24852187 |
2014 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Positive mCEA results were observed frequently for adenocarcinoma patients and were recognized as a suggestive prognostic factor by stepwise regression analyses (p = 0.0472).
|
22252332 |
2012 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The positive rates for CEA in adenocarcinoma and squamous cell carcinoma patients were 23.8% and 26.8%, respectively.
|
21397974 |
2011 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Carcinoembryonic antigen (CEA) is a tumor-associated protein expressed on a variety of adenocarcinomas.
|
19118044 |
2009 |